Please login to the form below

Not currently logged in
Email:
Password:

MPDL3280A

This page shows the latest MPDL3280A news and features for those working in and with pharma, biotech and healthcare.

Roche gets first approval for PD-L1 inhibitor Tecentriq

Roche gets first approval for PD-L1 inhibitor Tecentriq

Specifically, the FDA has approved atezolizumab (MPDL3280A) - which will be sold as Tecentriq - for people with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Roche sees the potential to combine these therapies with other immunotherapies already in its oncology portfolio, such as MPDL3280A, which targets the PD-L1 receptor on cancer cells.  .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics